Lawsuit claims video shows Bishop’s Falls guards assaulting unconscious inmate in dentist’s chair | Canada | News

An inmate at a central Newfoundland prison is filing multiple lawsuits, including against corrections officers and a Gander oral surgeon, following an incident that reportedly happened at the surgeon’s office.

The Telegram has learned the man — an inmate at Bishops Falls Corrections Centre whose name is not being made public yet — alleges he was medically sedated at the oral surgeon’s office last month, when a corrections officer was video-recorded performing a dental procedure on him.

The video is believed to have been taken by another corrections officer, while two dental assistants were in the room at one point of the procedure.

The two corrections officers, who took the inmate to the oral surgeon’s office for an undisclosed procedure, were recently escorted out of the Bishop’s Falls facility by RCMP officers, a source told The Telegram earlier this week.

On Tuesday, both the RCMP and the Justice Department turned down requests for comment.

“My first reaction was shock and disbelief. With all due respect to my client. I thought it was incomprehensible and thought maybe he misapprehended what had happened.”

However, when contacted by The Telegram Wednesday, St. John’s lawyer Bob Buckingham confirmed he has been retained to represent the inmate and will file the lawsuit “fairly quickly” on his behalf.

“I haven’t heard of this happening in recent times in Newfoundland,” Buckingham said.

He said the lawsuits will claim battery, assault and breach of trust against the corrections officers; professional negligence and a breach of contract against the oral surgeon and the oral surgeon’s office; breach of trust by the corrections services and the provincial government, as well as vicarious liability against the provincial government, as it is alleged to have happened while corrections officers were on duty.

Buckingham said his client was unconscious at the time of the alleged incident, having been medically sedated, and had no knowledge of what happened when he left the dentist’s office a short time later. He said he learned about it and the video later from corrections administration.

“He understands one of the corrections officers took a video of this, which made the rounds within corrections services,” said Buckingham, adding that both the corrections administration and the RCMP are in possession of the video.

Buckingham said he was appalled to hear what the inmate says happened to him.

“My first reaction was shock and disbelief,” he said. “With all due respect to my client, I thought it was incomprehensible and thought maybe he misapprehended what had happened.

“It’s a very difficult set of circumstances to believe, given a professional involving a dentist and corrections officers who were there for his protection, and the inmate being under medically induced sedation.

“But types of egregious breaches of trust do happen in our province,” added Buckingham, who also represents the family of Jonathan Henoche, an inmate who was killed in segregation at Her Majesty’s Penitentiary in November 2019, in lawsuits against the corrections officers, the prison and the provincial government.

He said

Read more

Coronavirus cases in Texas surpass 900,000, state data shows

Coronavirus cases in Texas surpassed 900,000 over the weekend, according to state estimates.

As of Sunday, some 904,855 cases of the novel virus were reported in the Lone Star State, with more than 4,000 new cases reported on Sunday alone. Overall, more than 18,000 lives have been lost to COVID-19 in Texas, including the 53 new fatalities reported on Sunday. 

As of Sunday, some 904,855 cases of the novel virus were reported in the Lone Star State. (iStock)

As of Sunday, some 904,855 cases of the novel virus were reported in the Lone Star State. (iStock)

Additionally, more than 5,600 people are currently hospitalized with COVID-19 in the state. 

Texas is No. 2 in the nation for the most cases of the deadly virus reported in the past seven days, according to data from the Centers for Disease Control and Prevention (CDC). Illinois has reported the most in the past week, with 44,570 cases. Texas, meanwhile, has reported 42,480 cases in the past seven days, per the CDC. 

WAYS TO REDUCE ELECTION DAY STRESS, ANXIETY

The news comes as some states are encouraging, but not requiring, face masks at the polls ahead of Election Day on Tuesday. While officials in some states have said they will require voters who refuse to wear a mask to cast their vote either curbside or at an isolated location, a federal appeals court in Texas halted an order that would’ve required voters to wear a face mask while at the polls.

ARE POLL WORKERS AT AN INCREASED RISK FOR CORONAVIRUS?

As of Monday, the U.S. had tallied over 9.2 million cases of coronavirus and more than 231,000 deaths. A number of regions are seeing a surge in cases, as health officials have urged the public to refrain from letting so-called “coronavirus fatigue” set in, especially as the U.S. heads into flu season.

Fox News’ Alexandria Hein contributed to this report. 

Source Article

Read more

CDC report shows how a Wisconsin summer retreat became a ‘superspreading’ event

A coronavirus outbreak raged through an overnight school retreat in Wisconsin during the summer, beginning with one student before ultimately infecting more than 90 percent of the teens and the counselors, according to a new report from the Centers for Disease Control and Prevention.

The six-week faith-based camp had required all attendees from 23 states and territories and two foreign countries to be tested and quarantined for the week prior to the retreat, which ran from July 2 to Aug. 11. However, shortly after arriving at the camp, a ninth grader who had tested negative for the virus at home developed symptoms including a sore throat, cough and chills. The student was then given a PCR test which came back positive, the CDC reported.

Excluding 24 attendees who had provided evidence through antibody testing of having already been infected with and recovered from the virus, 91 percent, or 116, of the 128 students who had not previously been infected with the virus were determined to have Covid-19 either with a positive PCR test or a diagnosis based on symptoms.

Although the boys, all of high school age, were required to wear masks when traveling to the camp, they were allowed to go without them once they arrived and to mingle freely. The students and 21 counselors slept in close quarters: the students living four to six per room in dormitories or eight per room in yurts, and the counselors staying together in dormitories and yurts.

After the ninth grader tested positive, he was quarantined with 11 of his close contacts. After the 11 contacts tested negative by rapid antigen tests, they were released from quarantine. However, during the first week of the camp, six of the 11, as well as 18 others, reported a new onset of mild symptoms. These students were given masks, but not isolated, and there was no contact tracing, the researchers wrote.

The Wisconsin Department of Health Services was notified of the outbreak July 15, and on July 28, the department tested 148 of the 152 retreat attendees. Antibody tests showed that91 percent of those who had not been infected prior to arriving at the camp, 116 out of 128, had developed an infection while there.

None of the teachers, who were quartered separately from the students and the counselors and wore masks during class and practiced social distancing at all times, tested positive for the disease.

All the illnesses were mild and there were no deaths or hospitalizations reported among those who caught the virus.

“The attack rate was extraordinary both in terms of the number infected, as well as the pace at which they were infected,” Dr. Stuart Ray, a professor of medicine in the division of infectious diseases at the Johns Hopkins School of Medicine in Baltimore, said.“It illustrates how hard it has been to control,” he said.

Given that the students and the counselors were allowed to mix freely and were not required to wear masks or practice social distancing, an outbreak

Read more

Organised ‘overkill’: China shows off rapid lockdown system after latest outbreak

BEIJING (Reuters) – Days after a 17-year-old girl tested positive for COVID-19 in a remote part of western China last week, health authorities said they had tested over 4.7 million people in the region.

FILE PHOTO: Chinese Foreign Ministry spokesman Wang Wenbin speaks during a news conference in Beijing, China July 27, 2020. REUTERS/Tingshu Wang

China’s strict formula of immediate lockdowns and mass testing even at the first signs of infection has been vital to its success in controlling the disease, allowing its economy to quickly recover from the crisis, officials say.

The highly orchestrated strategy – described as “overkill” even by its own proponents – is unique among major economies at a time when Europe and the United States are facing a massive surge of new cases and often chaotic policies.

At the time the girl was diagnosed, the Kashgar region of Xinjiang had reported no new cases for almost 70 days.

“China has taken the most comprehensive, strictest and most thorough control and prevention measures since the COVID-19 pandemic started,” foreign ministry spokesman Wang Wenbin said on Wednesday.

“The facts show China’s measures are effective.”

Key to the programme are factors unique to China, including the Communist Party’s tight grip on all aspects of society.

Authorities have unimpeded access to personal information as part of an expansive surveillance network, which has played a major role in tracing infections.

The government has also quickly enlisted the help of businesses, which are churning out tens of millions of test kits, and tightly controls their pricing and distribution, issues which have severely set back efforts to contain the disease in other countries.

China has reported just 2,382 cases since June. By contrast, Germany and France are set to follow Italy and Spain back into partial lockdowns, as Europe reported a record 230,000 cases in one day earlier this week, while U.S. cases are set to hit 9 million soon.

MASS TESTINGS

In August, Beijing ordered all major hospitals in the country to offer testing, and said there should be one urban testing base constructed for every million residents, with the capacity to scale up to 30,000 tests a day in a local outbreak.

Regions are also required to share resources, in sharp contrast to the early days of the outbreak, when several cities were accused of stealing equipment from each other.

The system, like all Chinese Communist blueprints, is highly structured around specific targets; testing teams should be able to complete a campaign within seven days.

Earlier this month, almost 11 million test results were delivered in around five days in the eastern port city of Qingdao. In Wuhan, the initial epicentre of the pandemic, over 9 million samples were taken over 10 days in May.

The mass testings are mandatory. Some are held in outdoor sporting venues and city parks, with hundreds of people lining up.

PUTTING PEOPLE AT EASE

Epidemiologists have called into question the efficacy of the mass testing events, noting some patients require multiple tests over time

Read more

Love Island’s Jack Fincham shows off fitness transformation

Jack Fincham showed off his abs (Picture: Jack Fincham/Rex)

Love Island star Jack Fincham looks a little unrecognisable in a new snap which sees him showing off his incredible fitness transformation.

The reality star’s hard work has clearly been paying off, as he showed off his abs in a mirror selfie.

Sharing a photo of his epic transformation, he wrote in the caption: ‘Dad bod.’

His friends and fans were quick to cheer him on, with fellow Love Island star and new dad Jamie Jewitt writing: ‘There he is, fighting fit mate 💪’.

Fitness influencer Jacqueline West added: Well done for the discipline Jack! Good luck,’ while former Love Islander Dom Lever simply told him: ‘I would.’

Good to know, Dom. Good to know.

Jack, 29, became a dad for the first time in January this year, welcoming his daughter Blossom with his friend Casey Ranger.

The reality star has since explained that he chose to keep his baby news quiet at first to give Blossom’s mum, who isn’t in the public eye, as ‘peaceful’ a pregnancy as possible.

Jack rose to fame on the fourth series of Love Island (Picture: ITV/REX)

Opening up on his reaction to finding out he was going to be a father, Jack admitted that the first thing he did was panic.

Speaking to The Sun in February, Jack confessed: ‘I’m not going to sit here and lie, at the start, I couldn’t get my head around it at all. I was like, “Sh*t, oh god!”

More: Love Island

‘I just wasn’t expecting it. I remember I was sitting in this bar and I panicked… you just don’t plan for it.’

Jack shot to fame on the fourth series of Love Island back in 2018, where he won the ITV2 dating show with his ex-girlfriend Dani Dyer.

Got a story?

If you’ve got a celebrity story, video or pictures get in touch with the Metro.co.uk entertainment team by emailing us [email protected], calling 020 3615 2145 or by visiting our Submit Stuff page – we’d love to hear from you.

MORE: Jack Fincham’s ex claims Love Island star has seen daughter only ‘three times in eight months’

MORE: Jack Fincham ‘devastated’ after crashing his new £35k Mercedes two months after car accident

window.fbApi = (function () {

var fbApiInit = false; var awaitingReady = [];

var notifyQ = function () { var i = 0, l = awaitingReady.length; for (i = 0; i < l; i++) { awaitingReady[i](); } }; var ready = function (cb) { if (fbApiInit) { cb(); } else { awaitingReady.push(cb); } }; var checkLoaded = function () { return fbApiInit; }; window.fbAsyncInit = function () { FB.init({ appId: '176908729004638', xfbml: true, version: 'v2.10' }); fbApiInit = true; notifyQ(); }; return { 'ready' : ready, 'loaded' : checkLoaded }; })(); (function () { function injectFBSDK() { if ( window.fbApi && window.fbApi.loaded() ) return; var d = document, s = 'script', id = 'facebook-jssdk'; var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) { return; } js = d.createElement(s); js.id = id; js.async = true; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); } if ('object' === typeof metro) { window.addEventListener('metro:scroll', injectFBSDK, {once: true}); } else { window.addEventListener('DOMContentLoaded', injectFBSDK, {once: true}); } })();

Source Article

Read more

Study in Nature Medicine shows superior patient outcomes in LLS’s Beat AML clinical trial

Rye Brook, NY (Monday, October 26, 2020) – Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.

The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.

In other key findings, the study demonstrated a paradigm shift in how patients diagnosed with AML should be treated, proving that using genetic information to match patients to targeted therapies leads to better survival rates than the traditional one-size-fits all treatment approach.

AML is an extremely fast-moving cancer of the marrow and blood, affecting 21,000 people in the U.S. a year, and killing 10,000. For decades patients have been given the same treatments almost immediately upon diagnosis because waiting allows the cancer cells to grow out of control. This standard of care involves either infusion of a combination of two chemotherapies, cytarabine and daunorubicin, or treatment with a so-called hypomethylating agent, a drug that unleashes signals allowing the cancer cells to die.

“The study shows that delaying treatment up to seven days is feasible and safe, and that patients who opted for the precision medicine approach experienced a lower early death rate and superior overall survival compared to patients who opted for standard of care,” said John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research of The Ohio State University, and one of the Beat AML leads and corresponding author of the study. “This patient-centric study shows that we can move away from chemotherapy treatment for patients who won’t respond or can’t withstand the harsh effects of the same chemotherapies we’ve been using for 40 years and match them with a treatment better suited for their individual case.”

Going on the Offensive Against AML


Recognizing the urgent need to do better for AML patients, LLS launched this clinical trial in fall 2016 to test multiple novel targeted therapies at major cancer centers across the U.S., in newly diagnosed AML patients aged 60 and older. In a historic first for cancer clinical trials, LLS is the first non-profit health organization to sponsor a trial and hold the IND (Investigational New Drug) application from the U.S. Food and Drug Administration. Beat AML partnered with Foundation Medicine Inc. to employ next generation genomic sequencing to rapidly analyze the patients’ cancer cells, and identify the patients’ AML subtype so they can be given a targeted therapy within a safe timeframe.

“The breadth of this collaboration, with every clinician, cancer center, pharmaceutical partner and all of the many operations and technical support companies, all unified in working toward the common goal of building a new model for tackling this challenging

Read more

Coronavirus live updates: COVID-19 positivity rates rising in 37 US states, analysis shows

The number of new cases of COVID-19 recorded across the United States has increased substantially, as has the number of new deaths from the disease, according to an internal memo from the U.S. Department of Health and Human Services that was obtained by ABC News on Monday night.

The memo, which is circulated among the highest levels of the federal government and is used to determine daily priorities for the agencies working on a COVID-19 response, said 40 U.S. states and territories are in an upward trajectory of new infections, while nine jurisdictions are at a plateau and seven others are in a downward trend.

There were 488,498 new cases confirmed during the period of Oct. 19-25, a 26% increase from the previous week. There were also 5,615 fatalities from COVID-19 recorded during the same period, a 15.1% increase compared with the week prior, according to the memo.

The national positivity rate for COVID-19 tests increased from 5.6% to 6.1% in week-to-week comparisons. Meanwhile, 22% of hospitals across the country have intensive care units that are more than 80% occupied. That figure is up from the summertime peak, when 17-18% of U.S. hospitals had 80% of ICU beds full, the memo said.

Arizona reported 848 COVID-19 hospitalizations on Oct. 21, its highest count since Aug. 26, according to the memo.

In the U.S. territory of Guam, which continues to be classified as a “red zone” for COVID-19 infections, an average of 89.7% of inpatient beds and 80.2% of ICU beds were occupied in the week ending Oct. 20, the memo said.

North Dakota saw a record high of 1,036 new cases on Oct. 20, surpassing the 1,000 mark of daily incident cases for the first time, according to the memo.

New Jersey reported 852 daily COVID-19 hospitalizations on Oct. 22, its highest since late July, the memo said.

Oklahoma reached a record 956 COVID-19 hospitalizations on Oct. 22. The previous record was set just two days earlier, according to the memo.

Utah reported an all-time high of 314 COVID-19 hospitalizations on Oct. 21, as several hospitals in the state reached capacity, the memo said.

ABC News’ Josh Margolin contributed to this report.

Source Article

Read more

Cold temperatures, vitamin A can help the body burn more fat, study shows

People looking to lose weight may start embracing the winter months after a new study found cold temperatures and increased vitamin A encourage fat burning.

The study, which was published in the journal Molecular Metabolism last week, explored the effects cold temperatures and vitamin A had on converting white fat, which is where excess calories are stored, to brown fat, which “stimulates fat burning and heat generation.”

More than 90% of the human body’s fat deposits are white fat, which is stored in the abdomen, bottom and upper thighs, the study shares.

Cold temperatures applied to mice was found to increase vitamin A production, which resulted in higher fat burning. 

Cold temperatures applied to mice was found to increase vitamin A production, which resulted in higher fat burning. 
(iStock)

LONDON MARATHON MEDALIST SARA HALL SAYS POSITIVITY AND FAITH HELPED HER ACROSS THE FINISH LINE

According to the findings, cold temperatures increased vitamin A levels, which helps convert white to brown fat, thus stimulating fat burning. Vitamin A reserves are mostly stored in the liver. Once cold was applied to the mice in the study, the increases in “the levels of vitamin A and its blood transporter, retinol-binding protein” led to a higher rate of fat burning as the white fat converted to brown as the body attempting to keep itself warm.

Alternatively, when “the vitamin A transporter ‘retinol-binding protein’” was blocked in mice, the fat did not “brown” and the mice were unable to protect themselves from the cold.

FITNESS INFLUENCER SHOWS HOW ‘BEFORE AND AFTER’ PHOTOS ARE MANIPULATED

The study is promising in finding solutions to dealing with weight gain and obesity. Though the study’s lead researcher, Florian Kiefer from the Medical University of Vienna, cautioned against taking large quantities of vitamin A supplements in an effort to lose weight.

WOMAN LOSES 117 POUNDS AFTER BEING TURNED AWAY FROM BRIDAL BOUTIQUE

“Our results show that vitamin A plays an important role in the function of adipose tissue and affects global energy metabolism. However, this is not an argument for consuming large amounts of vitamin A supplements if not prescribed, because it is critical that vitamin A is transported to the right cells at the right time,” explains the MedUni Vienna researcher. “We have discovered a new mechanism by which vitamin A regulates lipid combustion and heat generation in cold conditions. This could help us to develop new therapeutic interventions that exploit this specific mechanism.”

Source Article

Read more

Study in Nature Medicine Shows Superior Outcomes for Patients in The Leukemia & Lymphoma Society’s Paradigm-Shifting Beat AML Clinical Trial

RYE BROOK, N.Y., Oct. 26, 2020 /PRNewswire/ — Patients participating in The Leukemia & Lymphoma Society’s (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.


Leukemia & Lymphoma Society logo (PRNewsfoto/The Leukemia & Lymphoma Society)

The Beat AML trial achieved its primary endpoint by showing genomic analysis of the leukemia cells to identify AML subtypes can be completed within an unprecedented seven days, giving patients, caregivers and their doctors ample time to make a more personalized treatment decision without risking the patient’s chance for survival.

In other key findings, the study demonstrated a paradigm shift in how patients diagnosed with AML should be treated, proving that using genetic information to match patients to targeted therapies leads to better survival rates than the traditional one-size-fits all treatment approach.

AML is an extremely fast-moving cancer of the marrow and blood, affecting 21,000 people in the U.S. a year, and killing 10,000. For decades patients have been given the same treatments almost immediately upon diagnosis because waiting allows the cancer cells to grow out of control. This standard of care involves either infusion of a combination of two chemotherapies, cytarabine and daunorubicin, or treatment with a so-called hypomethylating agent, a drug that unleashes signals allowing the cancer cells to die.

“The study shows that delaying treatment up to seven days is feasible and safe, and that patients who opted for the precision medicine approach experienced a lower early death rate and superior overall survival compared to patients who opted for standard of care,” said John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research of The Ohio State University, and one of the Beat AML leads and corresponding author of the study. “This patient-centric study shows that we can move away from chemotherapy treatment for patients who won’t respond or can’t withstand the harsh effects of the same chemotherapies we’ve been using for 40 years and match them with a treatment better suited for their individual case.”

Going on the Offensive Against AML

Recognizing the urgent need to do better for AML patients, LLS launched this clinical trial in fall 2016 to test multiple novel targeted therapies at major cancer centers across the U.S., in newly diagnosed AML patients aged 60 and older. In a historic first for cancer clinical trials, LLS is the first non-profit health organization to sponsor a trial and hold the IND (Investigational New Drug) application from the U.S. Food and Drug Administration. Beat AML partnered with Foundation Medicine Inc. to employ next generation genomic sequencing to rapidly analyze the patients’ cancer cells, and identify the patients’ AML subtype so they can be given a targeted therapy within a safe timeframe.

“The breadth of this collaboration, with every clinician, cancer center, pharmaceutical partner and all of the many operations and technical support companies, all unified in working toward the common goal of building a new model for tackling

Read more

Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today two patients have demonstrated noticeable signs of improvement following treatment with leronlimab (PRO 140) in helping their recovery from stroke.

The most recent stroke patient, a physician in Mississippi, requested leronlimab, which was administered to him under Mississippi’s recently expanded “Right to Try” statute. The physician’s son, commenting on his father, stated, “He is doing good. Yesterday, he received his second treatment. He said he has been feeling better, and he thinks it is working. He said parts of his body and face that have been numb are starting to change/wake up.”

Scott A. Kelly, M.D., CytoDyn Chairman of the Board, Chief Medical Officer and Head of Business Development, commented, “We are encouraged by leronlimab’s potential to help patients recover from stroke and traumatic brain injury. Independent research has concluded CCR5 is upregulated in neurons after stroke, blocking CCR5 induces motor recovery after stroke, and CCR5 antagonism may enhance learning, memory, and plasticity. CCR5 is rapidly becoming an important target for neural repair in stroke and traumatic brain injury. Our recent data that leronlimab crosses the blood-brain barrier with 70-75% receptor occupancy of the CCR5 receptors in the brain (Macaque model) is encouraging for the potential to enhance recovery in stroke and traumatic brain injury and explore a variety of central nervous system pathology.”

A second stroke patient was receiving treatment with leronlimab as part of her therapy for breast cancer. The treating physician noted her partial paralysis was mitigated relatively quickly, which may have been causally related to the posited role of CCR5 in stroke.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “Leronlimab’s ability to cross the blood-brain barrier potentially presents numerous opportunities for the treatment of patients suffering from diseases related to the central nervous system. Therefore, we are accelerating the filing of a Phase 2 protocol to evaluate leronlimab’s potential as a therapeutic for stroke recovery. We continue to focus our energies on our most important task of enrolling more patients in our severe-to-critical COVID-19 Phase 3 trial as quickly as possible. In addition to moving forward rapidly to complete our Biologics License Application for HIV, in multiple countries, our extensive plan includes filing a protocol and IND for Phase 2 clinical trials for both stroke and Long Haulers COVID-19 indications. We continue to strongly believe leronlimab has the potential to provide therapeutic benefit to patients suffering from a variety of diseases, and this incredible prospect drives our management team every day. CytoDyn is committed to fulfilling this obligation to patients of the world.”

About Leronlimab’s Ability to Cross BloodBrain Barrier
The blood-brain barrier (BBB) mediates the communication between the periphery and the central nervous system (CNS). The BBB separates the circulation from the brain. It is a highly selective permeable border

Read more